Welcome to the DZIF -
the German Center for Infection Research

Community-Acquired Infections at Mucosal Interfaces

Hepatitis

HIV

Infections of the Immunocompromised Host

Healthcare-Associated Infections

Malaria and Neglected Tropical Diseases

Emerging Infections

Novel Antibiotics

Tuberculosis

The image shows a highly magnified electron micrograph of several oval, slightly rough Escherichia coli bacterial cells. The colour of the image is a reddish tone. The background is dark and highlights the bacteria.

Oct 21 2024

Chemical trick activates antibiotic directly at the pathogen

Oct 18 2024

Vaccine against the MERS coronavirus tested as safe and effective in phase Ib clinical trial

The —MERS stands for “Middle East Respiratory Syndrome”—causes severe respiratory diseases with a high rate. To date, there is neither a nor a specific treatment. The

Oct 17 2024

Scientists sound the alarm over lack of antibiotics

According to the WHO, (AMR) is one of the ten greatest threats to global health. In the EU alone, around 35,000 people die every year from antibiotic-resistant infections. The

Illustration of the intestinal epithelium with bacteria

Oct 11 2024

Microbiome research: Small RNA molecules play crucial role in the microbial colonisation of the gut

The intestinal is currently the subject of intensive research, as it is of great importance for human health. Intestinal bacteria play an essential role in the defence against dangerous

Sep 10 2024

INCATE marks its third anniversary of successfully supporting innovators fighting antimicrobial resistance

INCATE (the INCubator for Antibacterial Therapies in Europe) is celebrating its third anniversary. Since its launch in August 2021, INCATE has been dedicated to supporting early-stage innovators, in

All news

DZIF promotes podcast:

Infektiopod

Listen in: In each episode, a team of three consisting of initiator Dr Till Koch, Dr Annette Hennigs and Dr Elena Terhalle discuss specific diseases and current research findings. The current 86th issue deals, among other things, with multi-resistant gram-negative pathogens and treatment options for resistance.

More information about the podcast

Cut-out from the cover of the 2022 annual report

pdf (3.36 MB)

DZIF Annual Report 2022

pdf (3.36 MB)

Video

Das zentrale Bioprobenregister im DZIF

Video

pdf (3.65 MB)

DZIF Annual Report 2021

pdf (3.65 MB)

Find Media Content

Hamburg - Lübeck - Borstel - Riems

Clinical Tuberculosis Centre

The Clinical Tuberculosis Centre provides the expertise and infrastructure for the optimisation, prevention, diagnosis and treatment of tuberculosis (TB) as well as for translating research results into clinical practice. The main objectives of the Clinical Tuberculosis Centre include coordinating clinical research activities involving the DZIF TB cohort. This cohort includes [...]

Hannover - Braunschweig | Heidelberg | München | Tübingen

Transplant Cohort

Medical data and biological samples obtained from transplant patients are collected and managed across Germany with the help of the DZIF Transplant Cohort. The data and samples form the basis of scientific studies which investigate the connections between numerous factors influencing an organ’s susceptibility to infection and organ function. In [...]

Tübingen

New strategies for specific eradication of Staphylococcus aureus

In this project, the scientists develop genetically engineered phage lysins and specific bacteriocins for the elimination of hospital germs such as Staphylococcus aureus, they clarify mechanisms of potential resistance mechanisms, and they analyse whether broad-spectrum or specifically acting agents have a more effective and lasting effect on colonization by [...]

Hannover - Braunschweig

Preclinical development of Amidochelocardins

The challenge of antibiotic drug development today is the discovery and optimisation of novel bioactive compounds that do not show cross-resistances with clinically applied antibiotics, ideally due to a novel mode of action (MoA) which adresses unexploited microbial targets. In the case of chelocardin, this antibiotic substance was identified several [...]